These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 12972492)

  • 21. When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step?
    Smolen JS; Weinblatt ME
    Ann Rheum Dis; 2008 Nov; 67(11):1497-8. PubMed ID: 18854512
    [No Abstract]   [Full Text] [Related]  

  • 22. Borreliosis in a patient treated with anti-TNFα therapy: first case.
    Bonnet N; Guis S; Drancourt M; Brouqui P; Berbis P
    J Eur Acad Dermatol Venereol; 2011 Mar; 25(3):367-8. PubMed ID: 20524947
    [No Abstract]   [Full Text] [Related]  

  • 23. ANCA-positive crescentic glomerulonephritis in a patient with rheumatoid arthritis treated with anti-tumor necrosis factor alpha.
    Alkhunaizi AM; Dawamneh MF
    Int J Rheum Dis; 2017 Nov; 20(11):1843-1847. PubMed ID: 26012729
    [No Abstract]   [Full Text] [Related]  

  • 24. The impact of escalating conventional therapy in rheumatoid arthritis patients referred for anti-tumour necrosis factor-alpha therapy.
    Bingham SJ; Buch MH; Tennant A; Emery P
    Rheumatology (Oxford); 2004 Mar; 43(3):364-8. PubMed ID: 14657509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Golimumab (simponi) for inflammatory arthritis.
    Med Lett Drugs Ther; 2009 Jul; 51(1316):55-6. PubMed ID: 19590489
    [No Abstract]   [Full Text] [Related]  

  • 26. Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis.
    Del Porto F; Laganà B; Lai S; Nofroni I; Tinti F; Vitale M; Podestà E; Mitterhofer AP; D'Amelio R
    Rheumatology (Oxford); 2007 Jul; 46(7):1111-5. PubMed ID: 17449484
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluating guidelines on continuation of anti-tumour necrosis factor treatment after 3 months: clinical effectiveness and costs of observed care and different alternative strategies.
    Kievit W; Fransen J; Adang EM; Kuper HH; Jansen TL; De Gendt CM; De Rooij DJ; Brus HL; van de Laar MA; Van Riel PC
    Ann Rheum Dis; 2009 Jun; 68(6):844-9. PubMed ID: 18625616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Secondary syphilis following tumor necrosis factor-α inhibitor treatment for rheumatoid arthritis.
    Asahina A; Ishii N; Tohma S
    J Dermatol; 2012 Feb; 39(2):199-201. PubMed ID: 21463364
    [No Abstract]   [Full Text] [Related]  

  • 29. Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis.
    Puéchal X; Miceli-Richard C; Mejjad O; Lafforgue P; Marcelli C; Solau-Gervais E; Steinfeld S; Villoutreix C; Trèves R; Mariette X; Guillevin L;
    Ann Rheum Dis; 2008 Jun; 67(6):880-4. PubMed ID: 18037625
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eligibility of rheumatoid arthritis patients for anti-TNF-alpha therapy according to the 2005 recommendations of the French and British Societies for Rheumatology.
    Fautrel B; Flipo RM; Saraux A
    Rheumatology (Oxford); 2008 Nov; 47(11):1698-703. PubMed ID: 18794185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Nodular skin lesions in a patient with rheumatoid arthritis under therapy with anti-tumor necrosis factor-α].
    Díaz Cuevas Z; Rodríguez-Lozano B; Campos Gutierrez S; Lecuona Fernández M
    Med Clin (Barc); 2014 Feb; 142(4):183-4. PubMed ID: 23877097
    [No Abstract]   [Full Text] [Related]  

  • 32. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
    Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An error in the revised anti-TNF therapy guidelines for adult RA.
    Deighton C; Ledingham J
    Rheumatology (Oxford); 2006 Sep; 45(9):1170. PubMed ID: 16769774
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis.
    Rémy A; Avouac J; Gossec L; Combe B
    Clin Exp Rheumatol; 2011; 29(1):96-103. PubMed ID: 21269578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.
    Hyrich KL; Lunt M; Watson KD; Symmons DP; Silman AJ;
    Arthritis Rheum; 2007 Jan; 56(1):13-20. PubMed ID: 17195186
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term efficacy and safety of add-on tacrolimus for persistent, active rheumatoid arthritis despite treatment with methotrexate and tumor necrosis factor inhibitors.
    Naniwa T; Iwagaitsu S; Kajiura M
    Int J Rheum Dis; 2018 Mar; 21(3):673-687. PubMed ID: 29314738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The prevalence of patients with rheumatoid arthritis in the West Midlands fulfilling the BSR criteria for anti-tumour necrosis factor therapy: an out-patient study.
    Yee CS; Filer A; Pace A; Douglas K; Situnayake D; Rowe IF;
    Rheumatology (Oxford); 2003 Jul; 42(7):856-9. PubMed ID: 12730544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early intervention in rheumatoid arthritis.
    Vasanth LC; Paget SA
    Am J Orthop (Belle Mead NJ); 2007 Jul; 36(7 Suppl):9-10, 15-7. PubMed ID: 17694189
    [No Abstract]   [Full Text] [Related]  

  • 39. [Review of the protective effects of tumor necrosis factor inhibitors in rheumatoid arthritis].
    Finckh A; Gabay C; Guerne PA
    Rev Med Suisse Romande; 2004 Sep; 124(9):547-50. PubMed ID: 15552748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor necrosis factor inhibitors for rheumatoid arthritis.
    Scott DL; Kingsley GH
    N Engl J Med; 2006 Aug; 355(7):704-12. PubMed ID: 16914706
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.